Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma PURPOSE: To prospectively compare cytogenetic and molecular cytogenetic analysis for the detection of ...

DNA methylation profiles in whole blood samples from 77 patients with CN-AML in The Cancer Genome Atlas (LAML cohort) were analyzed. Individual 5’-cytosine-phosphate-guanine-3’ (CpG) sites were ...

Panelists discuss how current risk stratification systems, particularly the European Leukemia Net 2022 classification for intensive therapy and the 2024 classification for lower intensity treatments, ...

Please provide your email address to receive an email when new articles are posted on . Black race independently predicted shorter OS and DFS. Prevalence of cytogenetic abnormalities did not differ ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

Black race is an independent prognostic factor for lower survival outcomes in AML, regardless of cytogenetics. Black patients with NPM1 mutations had poorer overall survival compared to White patients ...

Bionano announced a significant study published in the American Journal of Hematology demonstrating the utility of optical genome mapping (OGM) in detecting structural variants associated with ...

The classification of AML is based on the French-American-British system in which morphologic and immunophenotypic features of blast cells divide AML into 8 distinct subtypes labeled M0-M7. M3 is the ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival (OS) rate of 77%, with no increase in toxicity compared to treatment without ...

Co announced that, data were presented at the EHA Meeting in a subset of 59 patients with unfavorable cytogenetics. Of these patients, 28 (47%) had secondary AML, 21 (36%) had de novo AML, and 10 (17% ...